Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 7,154 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $32.84, for a total transaction of $234,937.36. Following the completion of the transaction, the executive vice president now directly owns 45,670 shares in the company, valued at approximately $1,499,802.80. This represents a 13.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total value of $45,276.48.

Ionis Pharmaceuticals Price Performance

NASDAQ IONS traded down $0.85 during trading on Friday, hitting $31.43. 1,371,506 shares of the company’s stock were exchanged, compared to its average volume of 1,525,691. The company has a market cap of $4.96 billion, a PE ratio of -12.88 and a beta of 0.35. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $31.40 and a fifty-two week high of $52.49. The stock’s 50 day moving average price is $35.63 and its two-hundred day moving average price is $41.17.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in Ionis Pharmaceuticals by 38.8% in the second quarter. Renaissance Technologies LLC now owns 249,514 shares of the company’s stock valued at $11,892,000 after buying an additional 69,800 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in shares of Ionis Pharmaceuticals by 4.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 10,255 shares of the company’s stock valued at $489,000 after acquiring an additional 430 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Amalgamated Bank now owns 9,657 shares of the company’s stock valued at $460,000 after acquiring an additional 454 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock valued at $363,000 after acquiring an additional 261 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in Ionis Pharmaceuticals during the 2nd quarter worth $252,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on IONS shares. Guggenheim reduced their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Piper Sandler reduced their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Two analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.